EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical Outcome Comparison between CT-Guided Versus all MRI-Guided Scenarios in Brachytherapy for Cervical Cancer: A Single-Institute Experience

P Dankulchai, T Prasartseree, W Sittiwong, Y Chansilpa, N Apiwarodom, J Petsuksiri, K Thephamongkhol, T Treechairusame, T Jitwatcharakomol, J Setakornnukul, A Teyateeti, W Rongthong und 6 weitere

Clinical Oncology · 2024

DOI: 10.1016/j.clon.2024.08.003 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Oncology, 2024. Verfasst von P Dankulchai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Brachytherapy, Uterine Cervical Neoplasms, Tomography, X-Ray Computed, Magnetic Resonance Imaging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Image-guided adaptive brachytherapy (IGABT) is the standard of care for patients with cervical cancer. The objective of this study was to compare the treatment outcomes and adverse effects of computed tomography (CT)-guided and magnetic resonance imaging (MRI)-guided scenarios. MATERIALS AND METHODS: Data of patients with cervical cancer treated using external beam radiotherapy followed by IGABT from 2012 to 2016 were retrospectively reviewed. CT-guided IGABT was compared with the three modes of MRI-guided IGABT: pre-brachytherapy (MRI Pre-BT) without applicator insertion for fusion, planning MRI with applicator in-place in at least 1 fraction (MRI ≥1Fx), and MRI in every fraction (MRI EveryFx). Patient characteristics, oncologic outcomes, and late radiation toxicity were analyzed using descriptive, survival, and correlation statistics. RESULTS: Overall, 354 patients were evaluated with a median follow-up of 60 months. The 5-year overall survival (OS) rates were 61.5%, 65.2%, 54.4%, and 63.7% with CT-guided, MRI PreBT, MRI ≥1Fx, and MRI EveryFx IGABT, respectively with no significant differences (p = 0.522). The 5-year local control (LC) rates were 92.1%, 87.8%, 80.7%, and 76.5% (p = 0.133), respectively, with a significant difference observed between the CT-guided and MRI ≥1Fx (p = 0.018). The grade 3-4 late gastrointestinal toxicity rates were 6% in the CT-guided, MRI ≥1Fx, and MRI EveryFx, and 8% in MRI PreBT. The grade 3-4 late genitourinary toxicity rates were 4% in the CT-guided, 2% in MRI PreBT, 1% in MRI ≥1Fx, and none in MRI EveryFx. No significant differences were observed in the oncologic and toxicity outcomes among MRI PreBT, MRI ≥1Fx, and MRI EveryFx. CONCLUSIONS: CT-guided IGABT yielded an acceptable 5-year OS, LC, and toxicity profile compared with all MRI scenarios and is a potentially feasible option in resource-limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyUterine Cervical NeoplasmsTomography, X-Ray ComputedMagnetic Resonance ImagingRadiotherapy, Image-GuidedHumansFemaleMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomeAged, 80 and overRadiotherapy Planning, Computer-Assisted

Stichwörter der Autor:innen

CT-guided IGABTCervical cancerHigh dose rateImage guided adaptive brachytherapy (HDR-IGABT)MRI-guided IGABT

Autor:innen und Institutionen

  • Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Electronic address: tissana.p@gmail.com.

Zitieren

APA

Dankulchai, P., Prasartseree, T., Sittiwong, W., Chansilpa, Y., Apiwarodom, N., Petsuksiri, J., Thephamongkhol, K., Treechairusame, T., Jitwatcharakomol, T., Setakornnukul, J., Teyateeti, A., Rongthong, W., Thaweerat, W., Suntornpong, N., Veerasarn, V., Tuntapakul, P., Chareonsiriwat, N., & Manopetchkasem, S. (2024). Clinical Outcome Comparison between CT-Guided Versus all MRI-Guided Scenarios in Brachytherapy for Cervical Cancer: A Single-Institute Experience. Clinical Oncology. https://doi.org/10.1016/j.clon.2024.08.003

Vancouver

Dankulchai P, Prasartseree T, Sittiwong W, Chansilpa Y, Apiwarodom N, Petsuksiri J, et al. Clinical Outcome Comparison between CT-Guided Versus all MRI-Guided Scenarios in Brachytherapy for Cervical Cancer: A Single-Institute Experience. Clinical Oncology. 2024. doi:10.1016/j.clon.2024.08.003

BibTeX
@article{Dankulchai2024,
  author = {Dankulchai, P and Prasartseree, T and Sittiwong, W and Chansilpa, Y and Apiwarodom, N and Petsuksiri, J and Thephamongkhol, K and Treechairusame, T and Jitwatcharakomol, T and Setakornnukul, J and Teyateeti, A and Rongthong, W and Thaweerat, W and Suntornpong, N and Veerasarn, V and Tuntapakul, P and Chareonsiriwat, N and Manopetchkasem, S},
  title = {Clinical Outcome Comparison between CT-Guided Versus all MRI-Guided Scenarios in Brachytherapy for Cervical Cancer: A Single-Institute Experience},
  journal = {Clinical Oncology},
  year = {2024},
  doi = {10.1016/j.clon.2024.08.003}
}
Kostenlos starten →